AstraZeneca boosts cancer portfolio with $320 million Neogene deal

Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis and Gilead.